Lumena Pharmaceuticals Gets $45M

San Diego-based Lumena Pharmaceuticals, a biopharmaceuticals firm developing treatments for liver disease, said today that it has raised $45M in a Series B funding. The funding was led by New Enterprise Associates, and also included Adage Capital Management, RA Capital Management, as well as prior investors Pappas Ventures, RiverVest Venture Partners and Alta Partners. As part of the funding, Ed Mathers of NEA will join the company's board. Lumena has now raised about $78M in total. Luemna is developing treatments for rare cholestatic liver diseases and nonalcoholic steatohepatitis. More information »